



(51) International Patent Classification:

A61B 5/00 (2006.01) A61B 5/04 (2006.01)
A61B 5/0245 (2006.01) A61N 1/37 (2006.01)

(21) International Application Number:

PCT/US2015/045159

(22) International Filing Date:

13 August 2015 (13.08.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/038,440 18 August 2014 (18.08.2014) US
62/038,437 18 August 2014 (18.08.2014) US
62/038,438 18 August 2014 (18.08.2014) US
14/819,889 6 August 2015 (06.08.2015) US

(71) Applicant: CAMERON HEALTH, INC. [US/US]; 4100 Hamline Avenue N., St. Paul, Minnesota 55112 (US).

(72) Inventors: KRZYSZTOF, Siejko Z.; 9523 Kirkwood Way, Maple Grove, Minnesota 55369 (US). HUEL-SKAMP, Paul; 1554 Albert St. N, St. Paul, Minnesota 55108 (US).

(74) Agent: SCHROEDER, Mark R.; 100 South 5th Street, Suite 600, Minneapolis, Minnesota 55402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: IMPLANTABLE MEDICAL DEVICE WITH SELF-CORRELATION MEANS AND WITH ANALYSIS MEANS FOR ESTIMATING CARDIAC RATE




FIG. 14

(57) Abstract: An implantable medical device is disclosed, the device comprising electrodes for sensing cardiac signals (320), self-correlation means (322) for generating a self-correlation function from the sensed cardiac signals and analysis means (324) for determining one or more estimates of cardiac rate (326) using outputs of the self-correlation means. Peak selector means (340) and tracking means (342) may also be included as secondary elements. The device may provide an alternative calculation of cardiac rate as a stand-alone rate detector or as a device for double-checking other rate calculations.

WO 2016/028611 A1

IMPLANTABLE MEDICAL DEVICE WITH SELF-CORRELATION MEANS AND WITH ANALYSIS MEANS FOR ESTIMATING CARDIAC RATE

CROSS-REFERENCE TO RELATED PATENT DOCUMENTS

5 The present application claims priority to US Patent Application No. 14/819,889, filed August 6, 2015, which claims the benefit of and priority to each of US Provisional Patent Application No. 62/038,440, filed August 18, 2014, and titled CALCULATION OF SELF-CORRELATION IN AN IMPLANTABLE CARDIAC DEVICE, US Provisional Patent Application No. 62/038,437, filed August 18, 2014, 10 and titled CARDIAC RATE TRACKING IN AN IMPLANTABLE MEDICAL DEVICE, and US Provisional Patent Application No. 62/038,438, filed August 18, 2014, and titled PEAK SELECTION FOR SELF CORRELATION ANALYSIS OF CARDIAC RATE IN AN IMPLANTABLE MEDICAL DEVICE, the disclosures of which are incorporated herein by reference. The present application is also related to 15 US Patent Application No. 14/819,817, filed on August 6, 2015 and titled CARDIAC RATE TRACKING IN AN IMPLANTABLE MEDICAL DEVICE (Attorney File No. 1001.3750101), and US Patent Application No. 14/819,851, filed on August 6, 2015 and titled PEAK SELECTION FOR SELF CORRELATION ANALYSIS OF CARDIAC RATE IN AN IMPLANTABLE MEDICAL DEVICE (Attorney File No. 20 1001.3751101), the disclosures of which are incorporated herein by reference.

BACKGROUND

Implantable defibrillators are designed to deliver an electrical stimulus to terminate certain deleterious arrhythmias. Such devices must accurately identify 25 dangerous arrhythmias (sensitivity). They must also avoid delivering electrical stimulus when not desired (specificity). Attaining high sensitivity and specificity in the discrimination of such deleterious arrhythmias is a challenge.

Typically treatable arrhythmias include ventricular fibrillation (VF) and/or polymorphic ventricular tachycarrhythmia (PVT). Other arrhythmias can include 30 monomorphic ventricular tachycarrhythmia (MVT), atrial fibrillation (AF), and atrial flutter (Flutter), with the atrial arrhythmias of AF and Flutter deemed supraventricular tachycarrhythmias (SVT). For some patients, MVT is treated by the implantable

defibrillator using anti-tachycardia pacing (ATP), while AF and Flutter are typically addressed by other therapies entirely. In addition, patients can experience exercise induced ventricular tachycardia (VT), which is typically not treated at all. Some patients experience bundle branch blocks and other conditions that can arise at
5 elevated rates, causing the signal shape (morphology) of the cardiac signal with each cardiac beat to change relative to morphology at slower rates. Implantable devices are expected to appropriately distinguish these various conditions and apply the correct therapy for only certain conditions.

Chen et al., in *Ventricular Fibrillation Detection By A Regression Test On The Autocorrelation Function*, *Med Biol Eng Comput.*; 25 (3): 241-9 (May, 1987), discuss
10 the use of an autocorrelation function (ACF) to identify ventricular fibrillation in which the ACF is performed. Chen et al. hypothesize that the peaks in the ACF output are expected to be periodic and/or regular and should pass a linear regression test when a ventricular tachycardia (VT) is occurring. Therefore, the results of the
15 ACF are subjected to a linear regression analysis and VF is declared if the linear regression fails to find a linear fit. Chen et al. limit their analysis to VF and VT and do not address the fact that the linear regression they discuss would also likely fail for supraventricular arrhythmias such as atrial flutter or atrial fibrillation for which defibrillation therapy is typically not desired. Moreover, adding a linear regression
20 test with ACF would create a very large computational burden for an implantable system.

Sweeney et al., in US Patents 8,409,107 and/or 8,521,276 discuss the use of an ACF applied to a transformation of detected cardiac signal using curve matching. The ACF would be applied to identify recurring curves. Such recurring curves could be
25 used to find heart beats from the transformed signal, which could be used to calculate rate. ACF is not directly applied to the time varying cardiac signal, however.

ACF in each of these examples involves a large number of computational steps to be calculated. To make ACF more useful in an implantable device, simplified methods and alternative methods which address the spectrum of potential arrhythmias
30 are desired.

OVERVIEW

The present inventors have recognized, among other things, that a problem to be solved can include the incorporation of a modified autocorrelation function into an implantable cardiac device. Modifications can be made to reduce the computational
5 burden of the correlation function and accommodate some of the difficulties which arise in the context of an implantable device monitoring cardiac function. The present subject matter can help provide a solution to the problem of enhancing sensitivity and specificity in implantable cardiac rhythm management devices.

The present invention comprises several separately implementable elements
10 which provide avenues for reliable use of ACF at lesser computational burden in an implantable device.

In a first aspect, the invention comprises a set of rules for the calculation of a Minimum Absolute Difference (MAD) function to construct a Self Correlation. The use of MAD facilitates a far simpler and less computationally intensive manner of
15 analyzing the cardiac signal than ACF.

In a second aspect, the invention comprises a set of rules for the identification and selection of candidate peaks within a Self Correlation or ACF to yield an estimate of heart rate.

In a third aspect, the present invention comprises a set of rules for tracking
20 cardiac rate over time using output peaks from either a Self Correlation or ACF.

The first, second and third aspects may each be used independent of the other aspects, or in any suitable combination such as first-second, first-third, or second-third.

In a fourth aspect, the present invention comprises an integrated system or
25 method in which a simplified Self Correlation of the first aspect is combined with the second and third aspects.

In various embodiments, devices and methods may use any of the first through fourth aspects either on a continuing basis or following a triggering event. The present disclosure is, in certain examples, directed to enhancements such that a
30 self-correlation function can take the form of a simplified ACF, such as an MAD, as further discussed below. Enhancements which that aid in selecting peaks within the

results of a self-correlation function are discussed still further in US Provisional Patent Application No. 62/038,438, filed August 18, 2014, and titled PEAK SELECTION FOR SELF CORRELATION ANALYSIS OF CARDIAC RATE IN AN IMPLANTABLE MEDICAL DEVICE, the disclosure of which is incorporated
5 herein by reference. Tracking analysis, such as that in US Provisional Patent Application No. 62/038,437, filed August 18, 2014, and titled CARDIAC RATE TRACKING IN AN IMPLANTABLE MEDICAL DEVICE, uses the results of peak selection to provide a rate estimate for use in therapy and other decisions over time, with added confidence based on repeated peak selection. Some examples of the
10 present invention may omit or use alternatives to these peak selection and tracking enhancements.

This overview is intended to provide an overview of subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further
15 information about the present patent application.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, which are not necessarily drawn to scale, like numerals may describe similar components in different views. Like numerals having different letter
20 suffixes may represent different instances of similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.

- Figure 1 shows a subcutaneously implanted cardiac treatment system;
- Figure 2 shows a transvenously implanted cardiac treatment system;
- 25 Figure 3 shows an overall method for generating a cardiac rate estimate;
- Figures 4-5 illustrate the analysis of data using a self-correlation function and differentiate such analysis from ACF;
- Figures 6-7 illustrate the analysis of $R[n]$ peaks to identify candidate cardiac rates and a cardiac rate estimate;
- 30 Figures 8A-8B illustrate one method of tracking cardiac rate;
- Figure 9 illustrates tracking of cardiac rate over time;

Figures 10-13 demonstrate several cardiac rate tracking steps using hypothetical examples;

Figure 14 is a block flow diagram showing an analytical approach;

Figures 15A-15B illustrate different scenarios linking together the calculation of R[n], Peak Selector, Tracker, and Therapy Decision blocks; and

Figure 16 is a block flow diagram for an overall method of cardiac signal analysis.

DETAILED DESCRIPTION

Figures 1-2 show implant locations for illustrative cardiac systems. The present invention may find application in a subcutaneous-only system as illustrated in Figure 1, or in a transvenous system as shown in Figure 2. Alternatives may include systems having multiple subcutaneous, transvenous and/or intracardiac elements, epicardial systems, or fully intravenous or intracardiac systems.

The illustrative system shown in Figure 1 is shown relative to a heart 10 and is intended to convey a subcutaneous implant that would take place over the ribs of the patient and beneath the patient's skin. A canister 12 is implanted near the left axilla, with lateral, anterior, or posterior positions being possible. A lead 14 couples the canister 12 to electrodes 16, 18 and 20, which are illustrated as implanted along the sternum of the patient, typically to the left or right thereof. The system in Figure 1 may include an external programmer 22 configured for communication with the implant 12.

The system in Figure 2 is a transvenous system, illustratively shown relative to the heart 30 again with the patient's ribs omitted for clarity. The canister 32 is in a high pectoral position, with the lead 34 accessing the vasculature and entering the heart. The lead 34 may include a superior vena cava coil electrode 36, a right ventricular coil electrode 38, and one or two ventricular sense/pace electrodes 40, 42. Again a programmer is shown at 44 and configured for communication with the implanted system. The system may further include a left ventricular lead (not shown).

Communication for either of the systems in Figures 1 or 2 may be inductive, RF, direct (that is, using the patient's own tissue as a communication medium), or via

any other suitable medium of communication. Such communication can be useful to configure the implanted system for sensing, therapy or other feature, to load new software or firmware for the implanted system, and to retrieve information about system operation such as device status, therapy history, diagnostic data (both device
5 and patient related), or other suitable data. The programmers may contain such circuitry as is needed to provide processing, memory, display, telemetry/RF communications and the like for these noted purposes.

The canisters in Figures 1 and 2 will typically contain operational circuitry for the implantable system. The operational circuitry may include a controller and any
10 suitable analog and/or digital circuits needed for signal processing, memory storage and generation of high-power electrical, low-power electrical and/or non-electrical outputs. For example, an analog to digital converter (ADC) can be a direct conversion ADC, a successive approximation ADC, a ramp comparing ADC, a Wilkinson ADC, an integrating, dual slope or multi-slope ADC, a pipeline ADC, or a
15 sigma-delta ADC. Other ADC types, a modifications and/or hybrids of any of these types, may instead be used as those skilled in the art will appreciate.

The operational circuitry may be coupled to suitable battery technology for an implantable device, with any of numerous examples well known in the art, and may use various capacitor technologies to assist in the short term build-up and/or storage
20 of energy for defibrillation or other high output purposes. For example, therapy delivery circuitry may include a combination of a transformer, diodes, and high power capacitors may be used to develop high voltages for storage on the capacitors, with switching circuitry for controlling delivery of the high voltages to the patient, for example, a flyback transformer circuit may be used with high power capacitors and an
25 H-bridge circuit, as is known to the skilled artisan. The leads and external shell for the canisters can be manufactured with various materials suitable for implantation, such as those widely known, along with coatings for such materials, throughout the art. For example, the canisters can be made using titanium, with a titanium nitride or iridium oxide (or other material) coating if desired, and the lead can be formed with a
30 polymeric material such as a polyether, polyester, polyamide, polyurethane or polycarbonate, or other material such as silicon rubber. The electrodes can be formed

of suitable materials as well, such as silver, gold, titanium or stainless steel such as MP35N stainless steel alloy, or other materials.

The location of system implant may vary. For example, the system shown in Figure 1 is a subcutaneous-only system located on the anterior and lateral chest
5 between the skin and ribcage of the patient. Other subcutaneous only systems (including systems without a lead 14, with multiple leads 14, or an array in place of lead 14) may be used with other anterior only placements and/or anterior-posterior, posterior only, left-right, etc. locations, including, for example, locations noted in US Patents 6,647,292, 6,721,597, 7,149,575, 7,194,302, each of which is incorporated
10 herein by reference, and other locations as well. Subcutaneous placement can include any location between the skin and ribcage, including sub-muscular.

Illustrative transvenous systems, in addition to that of Figure 2, include single chamber, dual chamber and biventricular systems. A fully intravenous system has also been proposed. Additional or other coatings or materials than those noted above
15 may be used, particularly for epicardial, transvenous or intravenous systems, leads and canisters. Systems may further include an implantable "seed" that can attach directly to the myocardium without a lead at all. Some systems may combine an implantable, intracardiac seed with a subcutaneous-only defibrillator, with the seed and defibrillator enabled for two-way communication such as commanded therapy
20 delivery and/or conveyance of sensed data.

Various alternatives and details for these designs, materials and implantation approaches are known to those skilled in the art. Commercially available systems in which the above methods can be performed or which may be configured to perform such methods are known including the Boston Scientific Teligen™ ICD and S-ICD™
25 System, Medtronic Concerto™ and Virtuoso™ systems, and St. Jude Medical Promote™ RF and Current™ RF systems. Such platforms include numerous examples and alternatives for the various system elements.

As shown and described there are various ways in which an implantable cardiac rhythm management device or system may be implemented with respect to the
30 current invention. In several examples, the methods and devices that are focused upon in the present invention include the ability to capture and analyze a far-field

cardiac signal. Some examples of far-field signals include a signal captured between two subcutaneously placed electrodes, or between a canister electrode and an intracardiac electrode. Near field signals and/or signals generated as a combination of near and far field signals may be assessed in other alternatives.

5 Figure 3 shows an overall method for generating a cardiac rate estimate. A function “R[n]” is calculated. The function, R, may be, for example, a self-correlation function as illustrated in Figures 4-5, below. The function R represents a series of comparisons performed by calculating a relatively large number (50 or more) comparisons between a comparator that is a portion of a signal, and the overall signal
10 itself, where the comparisons are performed by repeatedly shifting the comparator relative to the overall signal.

R is discussed herein as a discrete function, rather than as a continuous function; in other examples, R may be a continuous function. In an example, R[n] may be a function that can be called periodically or it may be generated on a
15 continuing basis. Briefly referring to Figure 5, an illustrative R[n] as calculated at a selected point in time is shown at 140, based on a scrolling comparison of a comparator 122 to a buffer 120, the buffer 120 having length M and comparator a length M/2, providing R[n] a length of M/2. One could think of R[n,t], where n has values representing an individual calculation of R at a time t. For example, Figure 10
20 shows three “R” functions -- at each of t1, t2 and t3, R was calculated for n = 0 to 400.

Using R[n] as calculated from step 60, a number of candidate peaks are identified at 62. Figures 6-7 provide examples of the identification of candidate peaks. Candidate peaks can be understood as representing a potential “rate” of cardiac events. A high match, as represented by a peak in R[n], suggests alignment of
25 the cyclic electrical waveforms associated with a heart beat. For example, if a peak of R[n] occurs at n = 90, and the sampling rate is 256 Hz, then the time between R[0] and the peak would be $90/256 = 352$ ms. For this example, shifting the comparator back in time by 352 ms generates a relatively higher match between the comparator and the original signal. The 352 ms can be referred to as the lag depth, and if it truly
30 is the interval between successive R-waves, it would correspond to 171 beats per minute (bpm).

Next the method determines whether a valid track exists, at 64. Tracking is the process of monitoring the outputs of the $R[n]$ calculation and peaks therefrom to determine whether a high-confidence cardiac rate can be reported. Figures 8A-8B show an illustrative method of rate tracking. Figure 9 shows another approach to rate tracking.

If a track already exists, the method includes determining whether to confirm one of the candidate peaks, as shown at 66. If no track exists, then peak tracking is performed as shown at 68 to determine whether a new valid track can be declared. Next, following either 66 or 68, the method concludes the iteration shown by reporting a rate and confidence.

In some instances, no high confidence rate will be reported. For example, an atrial arrhythmia that is conducted to the ventricles may be characterized by unstable periods between ventricular depolarizations. As a result, the measured ventricular rate can be highly variable. When the ventricular rate is highly variable, $R[n]$ may produce only relatively low peaks, or may not produce consistently similar peaks during iterative calculations. As a result, the output rate from the entire procedure may either be missing or may be reported with only low confidence at block 70. Figures 10-13 illustrate an example showing several iterations of the method of Figure 3. Figure 14 illustrates in a block flow diagram a manner of analyzing data generally consistent with Figure 3.

In an example, the output rate and confidence can be used to confirm or call into question the cardiac rate as calculated using a more conventional process. For example, a device may use a default beat detection scheme in which the received cardiac signal, following amplification and filtering, is compared to a detection threshold. Some illustrative beat detection approaches are shown in, for example, US Patents 8,565,878 and 5,709,215, the disclosures of which are incorporated herein by reference. Crossings of the detection threshold can then be presumed to represent beats or R-waves, and various known methods can be used to identify and eliminate detection threshold crossings that are caused by noise or overdetections. See, for example, US Patents 7,248,921, 8,160,686, 8,160,687, 8,265,737, and 8,744,555, the disclosures of which are incorporated herein by reference.

The remaining detected beats or R-waves, and intervals therebetween, can be used to calculate rate. The present invention, in some embodiments, is used to double-check the rate calculated using such methods. Such double checking can be called as needed or provided on a continuing basis. For example, a double check may
5 be performed to confirm rate prior to therapy delivery, or prior to preparations for therapy delivery. In some embodiments, the present invention may provide a rate estimate which can override the rate as calculated using other methods such as beat detection.

In another example, a double check may be performed to confirm accurate
10 event detection as a way of verifying a sensing configuration where, if the sensing configuration is not verified, a sensing vector may be changed. In other embodiments, elements of the present invention can be used to provide rate calculation by default, or may be the sole source of rate calculations.

Figures 4-5 illustrate analysis of data using a self-correlation function and
15 differentiate such analysis from ACF. Figure 4 shows a sensed ECG signal at 100. The signal can be treated as a buffer of length M , as shown at 102. The calculation of $R[1], R[2] \dots R[M-1]$ is illustrated at 104. Each calculation of $R[n]$ is performed, in ordinary ACF, by multiplying (via dot product) a portion of the buffer and a portion of the comparator, with the comparator shifted in time relative to the buffer. The
20 comparator itself is simply a copy of the original buffer. Because of the shifting in time, a correction factor is needed as shown at 106, since the dot product is calculated using fewer and fewer data points as the overlap is reduced in size with each successive calculation of $R[n]$. The shifting of the comparator may be referred to as a lag depth. The full calculation can be quite burdensome for an implanted device
25 given the large number of operations required. Several simplifications are provided to facilitate an implantable system-based analysis.

A first simplification is to replace the multiplication to calculate a dot product with subtraction. The absolute value of the subtraction result yields a Minimum Absolute Difference (MAD). Swapping the dot product out and instead using MAD
30 will reduce the number of required calculations by an order of magnitude or more, with minimal reduction in accuracy.

Next, to eliminate the correction factor for overlap 106, the buffer 110, having length M , is divided in half, to provide a sample portion $M/2$ and an available lag depth 114. Then the iterative comparisons identify the area of difference between the sample 112 and the buffer 110. As shown at 116, the result is $M/2$ total comparisons
5 from a lag depth of zero to a lag depth of $M/2$.

An additional simplification may be performed in some embodiments by compressing the input data. For example, a system may perform analog-to-digital conversion of the cardiac signal at a rate of 256 Hz. The calculation of $R[n]$ maybe performed on a limited or compressed version of the original signal, reducing the
10 number of calculations again (though at the cost of calculations needed for downsampling, which may already be performed to facilitate data storage).

In a dynamic example, the sampling rate itself, or degree of compression of sampling rate, can be adjusted in light of the detected cardiac rate from one or more preceding iterations. For example, if a given calculation finds a relatively high
15 cardiac rate, the uncompressed version of the original signal may be used, while if a calculation finds a relatively low rate, a compressed version of the original signal may be used instead.

Turning to Figure 5, an example calculation of $R[n]$ at a particular point in time is shown. The ECG is shown at 120, as stored by a buffer having a length M .
20 The comparator for the self-correlation is shown at 122, and comprises the half of the buffer 120 having the most recently detected samples. Preferably, the length of M is enough such that at least 2 beats will fit within the comparator during benign rate (such as 60 bpm). Thus in an illustrative example, the buffer 120 has a length of about 4 seconds and the comparator 122 has a length of about 2 seconds. Another
25 example has a buffer 120 length of about 2 seconds and a comparator 122 with a length of about 1 second. Other sizes may be used. In some examples, the invention is characterized by having a buffer large enough to ensure at least two cardiac cycles occurring at a defined lowest needed rate would be captured, where the lowest needed rate may be in the range of 60-120 bpm. In further illustrations, the buffer length
30 could be from 1.5 to 6 seconds and the comparator length is between 750 milliseconds and 3 seconds. In the examples shown herein, the comparator is half the length of the

buffer; in other examples, the comparator may be between one-tenth to one-half of the overall buffer length.

A number of additional adjustments are contemplated. In some examples, the length of the buffer and/or the length of the comparator may be adjusted in light of an estimated heart rate or a history of heart rates. For example, at slower heart rates, the buffer and comparator lengths may be too short to capture multiple cardiac cycles, which is desirable to obtain an accurate result. Therefore, a dynamic approach may be adopted in which the buffer and comparator lengths are adjusted in light of a one or more previous rate calculations, to a longer length with slower heart rates, and a shorter length at higher heart rates. To reduce power consumption, the periodicity with which the overall function is called may be adjusted as well so that the buffer length does not cause data to be analyzed more than twice, for example. In specific examples, the buffer length can be at least twice, or thrice, the inverse of the cardiac rate, and the period at which the function is called is selected to be equal to the inverse of the previously detected cardiac rate or an average of several rate preceding rate calculations.

In another example, a longer buffer and/or comparator period may be selected for use under certain device states. For example, following delivery of a high-voltage therapy (defibrillation or cardioversion, for example), a longer buffer and/or comparator can be selected. In another example, if a noise flag is provided (for example by identifying a period or set of noisy event markers such as defined in US Patent 7,248,921, which is incorporated herein by reference), a longer buffer and/or comparator may be selected. For these long/short buffer/comparator examples, some embodiments may set a default length of a two second buffer and one second comparator, and switch to a four second buffer and two second comparator, for example. Other durations and types may be selected.

In another dynamic example, if one or more indicators of variable intervals between cardiac R-waves are identified, a longer buffer and/or comparator length may be selected. For example, if the P-wave can be observed, absence of the P-wave suggests an atrial arrhythmia which can cause variable R-R intervals. For another example, if a correlation waveform analysis, in which QRS complexes are compared

to one another or to a template, shows the morphology of the cardiac signal is unchanging, but intervals between R-waves as calculated using ordinary R-wave detection, for example, again, the combination suggests an atrial arrhythmia. Other markers are noted, for example, in US Patents 8,457,737 and 8,942,802, the
5 disclosures of which are incorporated herein by reference. Using one or more of these markers, then, the buffer and comparator lengths may be increased by 50% or 100% over standard lengths noted above (such as 1 second/2 seconds) when atrial flutter or atrial fibrillation are suspected.

As shown at 124, an MAD function is applied in this example, and is then
10 normalized using the maximum of the MAD across all of the comparisons made for a particular iteration of $R[n]$. This yields a result that is graphed at 126. The resulting graph includes a peak at 130, which corresponds to the zero lag depth calculation, during which the MAD would be zero, giving an output of 1. The next peaks 132, 134 and 136 each correspond to points in time where the MAD is calculated while the
15 R-wave peaks in the comparator are aligned with a set of R-wave peaks from the buffer. For example, if peak 138 of the comparator is aligned with peak 140 of the buffer, this would also align the adjacent peaks if the R-wave intervals are similar, giving a small absolute difference at that particular alignment. In the analysis, the zero lag depth calculation is typically ignored.

20 Other peak alignments between the comparator 122 and the buffer 120 may generate lesser peaks in $R[n]$. For example, peak 142 occurs when peak 138 of the comparator is aligned with the T-wave at 144. This positioning creates a smaller MAD output which, once normalized using formula 124, would generate a noticeable but small peak in $R[n]$. Normalizing with a formula such as that at 124 facilitates
25 comparison to fixed thresholds to distinguish between relative peaks within a poorly matching signal, and meaningful peaks showing alignment and matching between the buffer and the comparator.

The $R[n]$ function may be calculated periodically. In one example, because the buffer and comparator take up fairly large blocks of time, such as more than one
30 second or even two seconds, there is no need to continuously recalculate $R[n]$. For example, the period between recalculations of $R[n]$ may be approximately the

duration of the comparator, or, in another example, approximately half the duration of the comparator. For example, if the comparator length is 2 seconds, the buffer may be 4 seconds long and the calculation of $R[n]$ could be performed at one second intervals. Thus, every second, the buffer would be updated and the comparator
5 reformed, and the sequence of comparison and time shifting would be repeated. Figure 10, for example, shows repeated calculation of $R[n]$ at t_1 , t_2 , and t_3 , hence, $R[n,t_1]$, $R[n,t_2]$, and $R[n,t_3]$ are shown at 200 of that figure. The illustrative examples in the various Figures herein suggest the use of an asynchronous calculation of $R[n]$. These are asynchronous insofar as the calculation is not linked or synchronized to a
10 beat detection performed by some other method. Other embodiments may instead use a beat-synchronous update or recalculation of $R[n]$. A hybrid embodiment may update synchronously to take advantage of microprocessor/microcontroller wakeup caused by beat detection, but may limit calculation of $R[n]$ to occur no more frequently than some desired metric. For example, calculation of $R[n]$ may be beat
15 synchronized at intervals of no less than one second. Figures 6-7 illustrate the analysis of $R[n]$ peaks to identify candidate cardiac rates and a cardiac rate estimate. Figure 6 shows the operation in a flow diagram, while Figure 7 provides a graphic example.

In Figure 6, beginning at block 150, the method starts with the identification of any peaks within $R[n,tk]$. In this example, peaks that are within 50% of the largest peak and that meet some minimum size criteria are reported forward to a peak tracker,
20 as indicated at 152. Tracking may be performed as shown below in Figures 8A-8B and 9, for example.

A set of largest candidates are then selected, as indicated at 154. In an illustrative example, a threshold may be set within the scaled calculation of R . For
25 example, using the formula 124 in Figure 5, the threshold for candidate peaks may be set at $R = 0.3$, such that in order to be considered a candidate, a peak must be larger than 0.3 times the largest peak. The largest peak will always occur at $R[0]$, as that is when the comparator and buffer are perfectly aligned and thus $R[0] = 1$. Any
subsequent peak greater than 0.3 may be a candidate peak. In an example, up to five
30 of the largest peaks greater than 0.3 (excluding the peak at $R[0]$) are treated as candidates.

As shown at 156, if any of the largest candidates have a lag depth which would place the candidate in the “tachy zone”, a tachy flag is set. A candidate peak is in the “tachy zone” if the lag depth of the peak is relatively small. This may be identified by asking whether there is a peak at $R[nt]$ where nt is less than a tachy threshold. For example, if the tachy zone flag is to be set for candidate peaks suggesting a rate above 160 bpm, and the sampling rate is 256 Hz, then a peak at $n < 96$ is in the tachy zone, since the peak occurs with a lag depth of less than 375 ms equating to a rate above 160 bpm. The tachy flag, if set, indicates that the analysis suggests possible tachycardia, regardless the rate it ultimately concludes is most likely correct.

Next, a first candidate peak is selected as shown at 158. Either of two rules for finding the candidate peak can apply: a peak having a lag depth that allows a rate to be found that is greater than 75 bpm and which is larger than the first-in-time peak by a chosen limit, δ , can be chosen, as shown at 160 or, otherwise, the first-in-time peak of the candidate peaks is chosen, as shown at 162. The first-in-time peak is the candidate peak having the least lag depth. The first rule, at 160, allows a peak which is significantly larger than the first-in-time candidate peak to be selected, as long as it is above a rate threshold. In the example, the rate threshold is at 75 bpm; other thresholds may be used.

In the illustrative example, the combination of 160 and 162 ensure that peaks associated with higher rates will be analyzed first and, to this extent, biases the method to seek out higher rate candidates. A bias toward higher rates may be desirable to minimize the risk of heart rate underestimation in the presence of a tachyarrhythmia.

Next, the candidate peak is analyzed by looking for and counting “pickets”, as shown at 164. The pickets are peaks at multiples of the lag depth of the candidate peak. Figure 7 shows an example of pickets. A first peak is found at a lag depth of 110 samples (corresponding to 140 bpm sampled at 256 Hz). This lag depth gives an R-R interval as shown at 180. Two pickets can be identified by observing additional peaks at lag depths of 220 samples and 330 samples, which are multiples of the lag

depth of the candidate. The pickets at 182 and 184 provide confirmation that the 140 bpm rate is likely the correct cardiac rate.

The counting of pickets can include an allowance for some variation in peak spacing. For example, the picket peaks should be equally spaced, within a maximum
5 tolerance. The tolerance can be defined as a function of the calculated heart rate, or may be set in terms of milliseconds or samples (n). For example, if a first peak is at a lag of 80 samples (313 milliseconds at 256 Hz), a picket would be expected to appear between 75 and 85 samples away (293 milliseconds to 332 milliseconds). A narrower or wider tolerance may be defined in other examples.

10 It should be noted in this example that the largest peak is not the first selected candidate peak. There are two reasons why this is so: first, the largest peak is not sufficiently large relative to the candidate peak to meet rule 160. In an example, to select a peak other than the first peak as a candidate, the later peak needed to be at least 30% larger than the candidate (making delta relative), which is not the case here.
15 In another example, delta may be a fixed value, such as 0.2 using the MAD formula 124 from Figure 5.

Second, the largest peak is at a lag depth corresponding to a rate of 70 bpm, again not meeting rule 160. In the example, to select a peak other than the first peak as a candidate, the later peak needed to be at a lag depth corresponding to a rate
20 greater than 75 bpm. Other thresholds may be chosen. The picket determination may require that the peaks used to establish subsequent pickets be among the largest N peaks or that each peak be larger than a predetermined threshold, such as a peak above 0.35 or 0.50 using the formula at 124 in Figure 5.

Both of rules 160, 162 can be modified in other examples.

25 For illustrative purposes, Figure 7 also illustrates a tachy zone 186. The tachy zone, in this example, covers a lag depth from zero to about ninety. This corresponds to an offset of up to ninety samples. In the illustration shown, 384 samples equate to 1.5 seconds, meaning a 4 ms sampling period. Ninety samples would correspond an RR Estimated Interval of 360 ms, equating to 167 bpm. As noted above, other
30 settings for the tachy zone may be used.

Returning now to Figure 6, the method proceeds by determining whether the picket test passed, as shown at 168. In an example, the picket test passes if there are at least two pickets identified relative to the candidate peak. In another example, multiple picket thresholds may apply depending on the lag depth of the peak under analysis. For example, in analysis with maximum lag depth N , a rule set may call for at least two pickets for a candidate peak having a lag depth of less than $N/3$, and at least one picket for a candidate peak having a lag depth greater than $N/3$ and less than $N/2$. This relative approach accommodates the fact that, for a candidate peak having a lag depth between $N/3$ and $N/2$, only one picket is possible, as the second picket would be at a lag depth greater than " N " itself. Such relativity is optional, and may be managed, at least in part, using the dominant peak test discussed below.

If the picket test is passed, the method does a final check for any large peak in the tachy zone, as shown at 170. In some, limited instances, a large number of peaks may be reported during a chaotic tachy event. In such a case, the decision to select only " N " largest candidate peaks at block 154 could fail to choose as a candidate a peak in the tachy zone. Therefore the test at 170 looks for any peak in the tachy zone which is within 30% of the size of the largest peak, but which did not get identified as a candidate. Additional illustrative discussions of a large tachy zone peak test are provided in US Provisional Patent Application No. 62/038,438, titled PEAK SELECTION FOR SELF CORRELATION ANALYSIS OF CARDIAC RATE IN AN IMPLANTABLE MEDICAL DEVICE, the disclosure of which is incorporated herein by reference.

If a large tachy zone peak is identified at 170, this peak is subjected to a picket test as well. If the peak chosen at 170 has pickets such that it passes the picket test, then the large tachy zone peak from block 170 is reported as the RR estimate at 174. Otherwise, as noted at 156, the tachy zone flag is set and the candidate peak that did pass the picket test at 168 will be reported as the RR estimate at 174.

In some examples, all candidates may be checked until one is found which passes the picket test and, if no picket test passes can be found for any of the candidate peaks, the method proceeds to block 172. Alternatively, only the first

selected candidate peaks is subject to the picket test at 168, and, upon failing the picket test once, the method goes to block 172.

Upon reaching block 172, a dominant peak test is applied. The dominant peak test determines whether there is a peak that is 30% larger than all other peaks in $R[n]$ (excluding the peak at $n = 0$). If so, then that dominant peak is identified as the RR estimate.

The dominant peak test 172 may also be limited to passing when the identified dominant peak is at a lag depth corresponding to a rate below a preset threshold, such as 60, 75 or 90 bpm. The rate limit may be included in block 172 as an acknowledgement that there may be no pickets in the analyzed data for a low rate peak. This is so because the time span of the $R[n]$ calculation may not be sufficient to produce a picket pattern for all heart rates, particularly lower heart rates with longer beat intervals.

For example, using a buffer of 3 seconds and comparator of 1.5 seconds length, the first picket for a peak at a lag depth of 800 milliseconds (75 bpm) would be at 1.6 seconds. Such a picket could not be identified given the buffer/comparator sizes, as the greatest lag depth is only 1.5 seconds given the 3 second/1.5 seconds buffer/comparator sizes. On the other hand, a dominant peak at a smaller lag depth, such as 500 milliseconds (120 bpm) would be expected to have two pickets in this scenario, and, absent any pickets, would not be treated as a highly likely RR estimate as there would appear to be less periodicity than would ordinarily be associated with a confident RR estimate. Additional discussion of a dominant peak test which may be used in at 172 is provided in US Provisional Patent Application No. 62/038,438, titled PEAK SELECTION FOR SELF CORRELATION ANALYSIS OF CARDIAC RATE IN AN IMPLANTABLE MEDICAL DEVICE, the disclosure of which is incorporated herein by reference.

If an RR estimate is calculated via one of the three possible avenues -- candidate peak passing the picket test (158-164-168), a large tachy peak (170) or the dominant peak test (172), the RR estimate can be reported out. A confidence grade can also be applied. In an example, three grades are available:

- HIGH confidence if either

- Rate > TachyThreshold with 3 pickets and $R > HCThreshold$, or
- Rate < TachyThreshold with 2 pickets and $R > HCThreshold$;
- MID confidence by default if no High or Low Confidence condition is met; and
- 5 - LOW confidence if
 - $R < LCThreshold$ or
 - 1 or fewer pickets and Dominant Peak Test 172 not passed

In this example, TachyThreshold can be set in a range calling for high rates, for example, over 150, 180 or 200 bpm. In some examples, TachyThreshold may be selected in light of the buffer and comparator size, in order to link to the quantity of pickets that could appear. The HCThreshold definition will be reliant on just how R is computed. In an example, given computation of R using the formula at 124 in Figure 5, HCThreshold is set at 0.65. Likewise, LCThreshold will be defined in a manner closely tied to the computation of R. In an example also using formula 124 from Figure 5, LCThrehsold is set to 0.35.

The confidence information may also be incorporated into the tracking steps shown in Figures 8A-8B. For example, switching from one track to another, or declaring a new track, may be accelerated in response to a high confidence rate, while such steps may be delayed for a low confidence rate.

20 In a Bigemini pattern, there are two alternating morphologies for ventricular depolarization or “R” waves. When a Bigemini pattern is analyzed using self correlation, it can be difficult to determine whether the output reflects R-wave and T-wave peaks, which alternate and have different morphologies, or two R-waves having a Bigemini pattern. Particular approaches to identifying Bigemini and/or jitter are shown in related US Provisional Patent Application No. ___ filed on even date 25 herewith and titled CARDIAC RATE TRACKING IN AN IMPLANTABLE MEDICAL DEVICE (Attorney File No. 5279.098PRV), the disclosure of which is incorporated herein by reference.

Figures 8A-8B illustrate one method of tracking cardiac rate. Starting at block 30 200 in Figure 8A, any suitable manner of finding $R[n]$, selecting a set of peaks and generating an RR Estimate are performed. The methods illustrated in Figures 4-7

provide various options for block 200. The tracking method begins by determining whether there is an existing or “active” track, as 202. If so, the method proceeds to B in Figure 8B.

If there is no existing track, the method determines whether a valid RR Estimate has been generated, as shown at 204. If no valid RR Estimate can be had from the prior analysis, no new track will be declared, and the method terminates with no track at 212 and awaits a next iteration. If a valid RR Estimate was found, the method next determines whether X out of the last Y RR Estimates (or attempts) are similar, as shown at 206. For example, if 3 of the last 4 RR estimates are similar, the test at 206 would be met for an X/Y of 3/4. In one example, a 3 of 6 rule is applied at 206. If the test at block 206 is met, then a new track is established at 208.

If the test at 206 is not met, a new track may still be established on the basis of a single very high confidence rate calculation. The definition of very high confidence may vary. In one example, the HIGH/MID/LOW confidence rules applied above may be used, and any RR estimate that is calculated with HIGH confidence would be sufficient to meet the rule at 210. In another example, a separate threshold for the very high confidence rule at 210 may be set. In one embodiment, block 210 is met when $R > 0.85$ in a system calculating R using the formula shown at 124 in Figure 5. If the rule at 210 is met, a new track is established as shown at 208. Otherwise, no new track is set, as noted at 212.

Turning to Figure 8B, a valid track exists, and it is determined whether the latest RR Estimate is within the Gate, as shown at 220. The Gate has a width, which can be defined in various ways. For example, the gate may be 40 milliseconds wide, or it may be 20 bpm wide. The Gate may be centered on a prior RR Estimate or average of 2-4 previous RR Estimates. In one illustration, the Gate is calculated by converting the most recent RR Estimate to bpm, and setting the upper and lower bound 10 bpm away. Thus, for example, if the most recent RR estimate is 400 ms, that converts to 150 bpm, and the Gate would be from 140 bpm to 160 bpm and an RR estimate between 429 ms and 375 milliseconds would be considered “in” the gate.

Gate width may also factor in rate variability. For example, the variability of a set of recent RR Estimates can be calculated by simply tracking how much change

there is one from one estimate to the next. The Gate width may be increased if the rate appears to be highly variable in this example.

If the RR Estimate is within the Gate, the method declares the track continued at 222. The RR Estimate is also reported out.

5 If the RR Estimate is not within the Gate, then the Coasting rules are applied. Coasting takes place when a valid track has been identified/defined, but an iteration of the RR Estimate calculation fails to yield a result that meets the track definition. The use of Coasting allows the track to continue and passes over temporary disturbances such as noise or PVC, for example. Coasting avoids gaps in the output RR Estimate
10 by holding the last known RR Estimate. Coasting can be particularly useful when a peak exists in $R[n]$ but fails, for whatever reason, to otherwise pass the rigorous tests in the peak selector for identifying the a candidate peak as an RR estimate. Coasting is available to salvage the RR Estimate for such peaks, but only for a limited time.

In the illustrative example, Coasting is not allowed to continue indefinitely
15 and a limit is applied, as shown at 224. If coasting is within its limits, the method continues via block 232 and continues on the track at 222. To limit coasting, various rules can be applied and each may have a different limit.

For example, as shown at 226, if no RR estimate or peaks are reported up from the calculation of R , there may be a first, "No Data" limit to the duration of coasting.
20 In an example, the system will only allow a single iteration of "No Data" before declaring the track lost at 236. Such a "No Data" condition can occur, for example, if noise has interrupted sensing and none of the peaks in $R[n]$ exceed a base threshold. A "No Data" condition can also take place if a polymorphic arrhythmia onsets, such that $R[n]$ simply fails to have any significant peaks.

25 Next, there is a coasting state in which no RR Estimate is produced, as shown at 228, with this state also requiring that there not be any of the reported peaks in the gate, as shown at 230. Thus, block 228 covers one set of circumstances in which rate estimate is lacking and the track is not being confirmed, while block 230 covers a state in which there is a lower confidence confirmation of the track, whether or not an
30 out-of-track RR estimate has been identified.

A fourth form of coasting can take place as part of a transition or “jump” to an alternate track, as noted at 232. In this instance the existing track continues until either an alternate track condition is met by having a “new” track declared using a similar determination as in 206 or 210 of Figure 8A.

5 As can be seen from blocks 226, 228, 230, 232, there are different inputs to the coasting state, each of which comes with somewhat varying confidence levels. For example, confidence in the underlying track or sensing reliability is low when no data is received 226, and not much better when there is no RR Estimate reported and none of the reported peaks fall within the gate 228. These two blocks 226, 228 may
10 be combined for a single limit in the range of 1-3 iterations before the coasting limit is exceeded. Alternatively, block 226 may have a lower costing limit (1-2 iterations) while block 228 has an equal or higher limit (1-4 iterations), with a combined limit matching the higher limit (1-4).

The alternate peak in gate condition, at 230, is a much higher confidence
15 condition, by suggesting that the track may still be valid, even if sensing a anomaly, such as noise, is present. This condition 230 may have a still higher coasting limit, in the range of 2-10 iterations or may be subject simply to an overall limit (in the range of 2-10 iterations) which would combine any coasting within any of 226, 228, 230 or 232.

20 Block 232, the Jump limit, is present to enable quick transition to a new track, without having to first wait for a declaration that the track is lost at 236 before assessing whether a new track exists. The Jump limit also prevents a shift to a new rate based on peaks that appear within an old, but no longer valid, track. When a coasting limit is met at 224 via the jump limit, the outcome follows a different path to
25 238. As a result, if the Jump limit is met, the method simply continues with a new track definition. To meet the Jump limit 232, in an illustrative example, the same rule as was applied at 206 may be applied to the new track. As noted at 232, the Jump limit may be applied just for high rate conditions, which are of greater concern generally than low rate conditions, using, for example, a limit in the range of 100-180
30 bpm, with 150 bpm being one example rate in particular.

The use of the Jump allows a quick transition to a higher rate RR Estimate, with a less stringent rule set when there is an existing track and a jump takes place. In the example, to declare a new track when no track has been identified would require a higher confidence in the new data than is required for the jump.

5 If the coasting limit is exceeded at 224, the track will be declared lost, as noted at 236. If the coasting limit is not exceeded, the coasting “state” can be recorded 234, with different coast states identified for each of the different coasting conditions 226, 228, 230, 232. While coasting, the track continues as shown at 222 until the next iteration is called.

10 Figure 9 illustrates tracking of cardiac rate over time. There may be various triggers for performing self-correlation, as noted at 240. For example, self-correlation may be a default, continuing analysis called by an implantable system throughout the life of the system. Alternatively, self-correlation may be called in response to an identified potential condition necessitating treatment, such as an elevated rate
15 condition. In one example, the cardiac rate may be calculated using conventional R-wave detection schemes (often by comparing the detected cardiac signal to a time varying threshold). If the identified rate crosses a threshold, the self-correlation methods may be initiated to confirm elevated rate. Thresholds may be set, for example, in the range of 100-180 bpm, or higher or lower, as desired.

20 In one example, a cardiac therapy system may use a number of intervals to detect (NID) approach or an X/Y filter to transition from unconcerned state into a therapy preparation and delivery state. For example, an X/Y filter may call for 18 out of 24 prior detected heart beats to be analyzed and considered treatable before therapy is delivered. For such a system, if X reaches a lower threshold, for example, 8/24, the
25 self-correlation may be called to begin analyzing and confirming (or rejecting) calculated rates before the 18/24 boundary is reached. Similarly, if an NID approach is used, an NID threshold that is below a therapy boundary may be used to trigger the self-correlation analysis.

 In another example, self-correlation may be called to periodically confirm
30 sensing integrity by calculating a cardiac rate for comparison to other rate calculation

methods/circuits. In some examples, the self-correlation shown in the present application may serve as the sole estimator of cardiac rate in an implantable device.

Once the analysis is triggered at 240, the self-correlation is performed at intervals, such that $R[n,t]$ is calculated for each of $t = \{0, 1, \dots, i\}$, as shown at 242, 244, 246. From this series of calculations, a rate track is sought and, if possible, established as shown at 248. The analysis may confirm or reject a calculated rate, as shown at 250.

In addition, the analysis may be used to confirm, accelerate or delay therapy delivery, as noted at 252. Returning to an above example, if the self-correlation is called once the cardiac rate identified by conventional R-wave detection crosses a threshold, if self-correlation confirms an elevated heart rate requiring therapy, a therapy threshold may be lowered. For example, if a system uses an X/Y counter set to 18/24, the counter may be reduced to 12/16 if self-correlation confirms a very high rate prior to the X/Y counter condition being met. In another implementation, the self-correlation RR estimate can replace a conventionally calculated heart rate for a specified period of time, quantity of detected events, or until a next calculation of $R[n]$ and analysis thereof is performed.

Figures 10-13 demonstrate several cardiac rate tracking steps using hypothetical examples. Figure 10 illustrates the initiation of a rate tracking activity. The self-correlation function is calculated at each of times t_1 , t_2 and t_3 , as shown at 260, 262 and 264. For purposes of understanding operation of this embodiment, a graph at 266 illustrates how the peaks of each $R[n]$ calculation align with one another. Looking at $R[n,t_1]$, the graph at 260 illustrates that three peaks above the $R=0.3$ threshold were found, at lag depths of approximately 95, 190, and 285 samples. Using the method of Figure 6, these three peaks 268, 270, 272 would be reported out of the peak analysis.

Next, again using the rules shown in Figure 6, the first peak 268 from $R[n,t_1]$ is chosen as a candidate peak. Pickets would then be sought. As illustrated, there are two pickets identified for candidate peak 268, to the additional peaks at 270 and 272. Thus the method of Figure 6 would confirm that peak 268 provides the RR estimate, while each of peaks 268, 270 and 272 would be reported to the tracking engine.

The RR Estimate from $R[n,t1]$ is shown in graph 266 at 274; the other peaks from $R[n,t1]$ are also shown as alternate peaks. Likewise, RR Estimates result from the analysis of the other two calculations at $R[n,t2]$ and $R[n,t3]$, as shown at 276 and 278. Here, no track has yet been declared. As a result, each of the RR Estimates may
5 be deemed to yield a medium-confidence rate estimate, until a track can be declared.

Turning to Figure 11, the matching of the results for each of $R[n,t1]$, $R[n,t2]$ and $R[n,t3]$ is sufficient to meet the track definition in Figure 8B using a 3/6 rule. Therefore a track gate is shown at 280 for use in assessing the next iteration of the self-correlation, at $R[n,t4]$. The newly calculated $R[n,t4]$ is shown graphically at 282.
10 In $R[n,t4]$, the peak associated with a T-wave comparison appears at 284 in addition to the much higher peak for the R-wave at 286. Again applying the rule set in Figure 6, the first peak is at 284, and could be chosen if the rule at 162 in Figure 6 controlled. However, the second peak at 286 is significantly larger than the first peak and appears at a lag depth that supports a rate greater than 75 bpm, meeting the rule at 160 in
15 Figure 6. Therefore peak 286 is selected for analysis, and is found as before to have two pickets (not shown) and is used to report out an RR Estimate. As shown at 288, the RR Estimate for $R[n,t4]$ is within the gate.

It should also be noted that the peak 286 that is used for the RR Estimate exceeds an HC Threshold for high confidence. Therefore, the RR Estimate at 288
20 would then be used for rate reporting by the tracker, with high confidence.

Figure 12 presents a different scenario for the calculation of $R[n,t4]$ after the track is established and gate is set at 290. Here, the output has changed dramatically from $R[n,t3]$ to $R[n,t4]$, as shown at 292. Using the rules of Figure 6, the first peak 294 is chosen as a candidate peak, however, no pickets are found because the next
25 significant peak, at 296, is too far away. There is also no dominant peak. As a result, no RR Estimate is calculated.

Looking at the updated overall graphic including $R[n,t4]$, it can be seen that gate 298 is empty, without an RR Estimate or an alternate peak therein. As a result, for $R[n,t4]$, the analysis is in a coasting state in Figure 12. Because no RR Estimate
30 could be calculated based on $R[n,t4]$, a rate would not be reported to the Peak tracker. Because the track continues in a coasting state, an output rate estimate would be

provided and, in an example, would be a value within the gate or could be the same as a previous output. Based on the empty gate at 298, the output rate estimate would be given a low confidence level.

Figure 13 presents another different scenario for the calculation of $R[n,t4]$ after a track has been established. Gate 300 is set for the analysis, however, $R[n,t4]$, as shown at 302, does not identify a peak that sits within the gate, as shown at 304, as the RR Estimate. Instead, a peak 306 at a lesser lag depth is identified as the RR Estimate. Thus the RR Estimate 308 sits away from the gate 304, though one of the alternate peaks in $R[n,t4]$ is within the gate.

Referring back to Figure 8B, the event shown in Figure 13 would trigger a coasting analysis using the tachy jump limit 232. Specifically, RR Estimate 308 is at a relatively short lag depth shown, in the example, as corresponding to a rate between 180 and 240 bpm. Given this is the first such RR Estimate, not enough information is available yet to declare a new track. This could be a momentary jump, or it could be the onset of a new rhythm. Until more data is received, the illustrative method will wait and coast with the track continuing. The output rate estimate would continue to be within the existing track. However, because the RR Estimate is outside of the gate, any rate estimate would be reported with low confidence. A Tachy flag would be set based on the large peak in the tachy zone.

Additional scenarios relating to the tracking examples in Figures 10-13 are provided in US Provisional Patent Application No. 62/038,437, and titled CARDIAC RATE TRACKING IN AN IMPLANTABLE MEDICAL DEVICE, the disclosure of which is incorporated herein by reference.

Figure 14 is a block flow diagram showing an analytical approach. The general approach is shown on the left-hand side of the Figure, beginning with receiving a sensed signal at 320. A self-correlation is performed on the sensed signal 320, as indicated at 322. The self-correlation analysis generates a result which is subjected to further analysis, 324. In several examples, this all leads to a rate output, as noted at 326.

Within the self-correlation 322, the analysis begins with the selection of the sample sets to work with, as shown at 330. For example, first and second sets of data

are selected, each set having a length. The first data set can have a length that is approximately half that of the second data set, and the second data set includes at least the first data set plus additional data.

The first and second data sets are then compared to one another, as shown at 5 332, across the available lag depth. In an example, if the second data set has a length $2N$, then the first data set has a length N and the available lag is also N . One example uses approximately one second of cardiac signal for the first data set, and two seconds of cardiac signal for the second data set. In other examples, different ratios may be used between the data sets. For example, the first data set can have a length N , with 10 the second data set having a length $3N$, giving an available lag depth of $2N$. In one example, the first data set has a length of about one second, and the second data set spans three seconds.

In several examples, the first data set length of about one second is optimized for true cardiac rates of 120 bpm and higher, since it will not contain two cardiac 15 cycles for slower true cardiac rates. A longer first data set, however, increases the computational burden. In one example, the first data set covers 1.5 seconds and the second data set covers 3 seconds, optimized for 80 bpm and higher. Other set sizes can be used. The analysis may cross the entire available lag depth, or only some portion thereof.

20 The comparison 332, as discussed above, may be performed using a dot product but, more preferably, is performed using a subtraction method to reduce the computational complexity and burden. This process at 332 can yield an output $R[n,t]$, where $n = 0$ to the maximum lag depth, and t denotes the time stamp of the analysis. The “ t ” notation is included here because the function may be performed iteratively, 25 for example, at 1-3 second intervals (or shorter or longer, as desired).

The total lag and sample sizes, in some examples, is selected to ensure at least two cardiac cycles will be included in the analysis when the cardiac rate is in a range of, for example, 60 beats-per-minute. For example, given a 256 Hz data capture, downsampled to 64 Hz, the total quantity of samples in the first data set could be 64 30 samples, and the second data set may have 128 samples, such that one second of data is compared to two seconds of data through a one-second lag depth.

Next, in some examples, the output of this comparison can be normalized, as noted at 334. Normalizing can include, for example, scaling the output of the comparison to a value between 0 and 1, in some embodiments, though the output scaling is generally an arbitrary function. Normalizing 334 may be linear in nature, or
5 can be performed using squares or square roots to generate smoothing functions or other functions that highlight features of the comparison output. For example, a complex approach may take the square root of the outputs of the comparison 332, scale these to a range from 0-1, and then square the output. In some examples, a simpler approach is taken to normalize to the maximum of the comparison 332. In
10 some examples, the normalization step 334 can be omitted.

Turning to the Analysis block 324, as noted in the various examples above, one approach is to include first a peak selection analysis, as shown at 340, to identify one or more peaks in the self-correlation function which can be identified as likely cardiac rates, and then a tracking analysis 342 to assess the output of several iterations
15 of the overall analysis to yield an even more confident rate estimate. Tracking 342 may also aid in the maintaining of rate estimates in the face of extraneous inputs such as noise, allowing the interpolation of likely cardiac rate even when the received signal from 320 is poor.

The combination of peak selection 340 and normalization 334 can be linked
20 together. In certain examples, normalization is done to a scale of 0 to 1, with the peak selection 340 configured to ignore peaks below 0.3, 0.25, or 0.2. While such values are useful for understanding the approach, in many systems normalization would be done to a range between 0 and N, where N is a power of 2. For example, if one byte of memory is used for R[n], this permits values between 0 and 255 for R[n], and
25 normalization 334 could be performed to use a full byte. Peak selection 340 would use a scaled threshold. For example, if peak selection uses 0.3 times N as a minimum peak threshold, then for a one byte R[n], 0.3 times 255 would give a minimum peak threshold of 76.5, meaning a peak of 76 would fall below the threshold, and a peak of 77 would meet the threshold.

In other examples, the tracking block 342 may be omitted. In some examples, the analysis 324 may be greatly simplified, for example, to simply pick the largest of the peaks output in the self-correlation function.

Illustrative examples may use the details provided in US Provisional Patent
5 Application No. 62/038,438, filed August 18, 2014, and titled PEAK SELECTION
FOR SELF CORRELATION ANALYSIS OF CARDIAC RATE IN AN
IMPLANTABLE MEDICAL DEVICE, in block 340. Another example uses the
details provided in US Provisional Patent Application No. 62/038,437, filed August
18, 2014, and titled CARDIAC RATE TRACKING IN AN IMPLANTABLE
10 MEDICAL DEVICE, in block 342. As noted above, the disclosures of these
provisional patent applications are incorporated herein by reference

Figures 15A-15B show several ways in which the R[n] Calculator, a Peak
Selector, an RR Estimate Tracker, and a Therapy Decision can be linked together. In
the example of Figure 15A, the R[n] Calculator 400 reports the output of an R[n]
15 calculation to a Peak Selector 402. The Peak Selector 402 provides an RR
Estimate(a) and a set of Peaks to the Peak Tracker 404. The Peak Selector 402 also
provides, in this example, the RR Estimate(a) to a Therapy Decision Block 506, along
with any Flags arising out of the Peak Selector 402 analysis as well as a
Confidence(a) indicator. The Therapy Decision Block 406 can use the RR
20 Estimate(a) from the Peak Selector 402 as well as any Flags and the Reported
Confidence(a) to determine whether a conventional rate estimate is likely correct or
incorrect. The RR Estimate Tracker 404 reports an RR Estimate(b) and Confidence to
the Therapy Decision 406.

For example, the Peak Selector 402 may identify an RR Estimate(a), but with
25 low Confidence(a), while the RR Estimate Tracker 404 identifies a different RR
Estimate(b) with higher Confidence(b), based on a secondary peak that meets an
existing Track and which either has one or more pickets or is in a tachy zone, even if
the reported RR Estimate(a) is not in the track. In that case, the Therapy Decision
block 406 may ignore the RR Estimate(a) and instead adopt RR Estimate(b).

30 In another example, if the RR Estimate(a) is reported with High
Confidence(a), but the RR Estimate Tracker does not find a peak in an existing track

and reports it is coasting, using a preserved, prior RR Estimate and reporting a low Confidence(b), the Therapy Decision block 406 may adopt RR Estimate(a) over RR Estimate (b).

Thus, in the example of Figure 15A, Therapy Decision block 406 is allowed to
5 select from between RR Estimate(a) and RR Estimate(b), using the reported
Confidences from each of the Peak Selector 402 and RR Estimate Tracker 404.

In the example of Figure 15B, the R[n] Calculator 420 again provides its
results to the Peak Selector 422. The Peak Selector 422 performs its function and
provides Peaks, an RR Estimate(a), any set Flags, and a Confidence(a) to the RR
10 Estimate Tracker 424. The RR Estimate Tracker 424 performs its function and
provides an RR Estimate(b), Confidence(b) and any set Flags to the Therapy Decision
block 426. Thus, in Figure 15B, the RR Estimate Tracker determines a single output
RR Estimate(a) with associated Confidence(b) to the Therapy Decision block 426.

One or more of the individual blocks in Figures 15A-15B may be separate
15 pieces of hardware in a single system, though two or more blocks may be integrated
in a single dedicated circuit. Alternatively, the separate blocks in Figures 15A-15B,
may be separate functional blocks in a larger software structure. For example, given a
stream (or stored stack) of data, a function call to Calculate R[n] 400/420 could be
performed, followed by a function call to perform Peak Selection 402/422 given the
20 output R[n], followed by a function call to Track RR Estimate 404/424 using the RR
Estimate(a) and Peaks from Peak Selection, which may all be used as inputs (along
with other data) for calling the Therapy Decision 406/426. In one example, blocks
400, 402 and 404 are provided on a dedicated circuit and the outputs of these blocks
are provided to a processor or controller where the Therapy Decision process is
25 performed.

In the embodiments shown in Figures 15A-15B (and other examples shown
above and below), an RR Estimate can be considered an estimate of cardiac rate.
Where a confidence measure is provided in association with an RR estimate and one
or more peaks, such can be treated as one or more possible estimates of cardiac rate.

30 Figure 16 illustrates an integration of two methods for identifying rate. A
conventional rate method is illustrated using block 500, where R-waves are detected

individually by comparing a detected signal to a threshold. Conventional R-wave detection may be used in block 500. Some illustrative examples appear in US Patents 8,565,878 and 5,709,215.

5 Detected R-waves are reported to a noise/overdetection removal block 502 which confirms the R-waves are likely cardiac events. Once the individually detected R-waves have been confirmed at 502, rate and shape (morphology) information are obtained 504 and provided to a therapy decision and/or delivery block 506. This conventional method then returns to a wait state 508 until the next R-wave detection.

10 The method also integrates a rate calculation using self-correlation, which can be called asynchronously (at fixed intervals, for example), or synchronously to the new detection 500, as desired. This wait state is depicted at 510. Upon activation, the self-correlation rate estimate is made using the combination one or more of calculating R[n], Selecting Peaks, and optionally Tracking an RR Estimate 512. A resulting RR Estimate is then reported at 514 to the Therapy Decision block 506, and
15 the wait state 510 is again entered. The RR Estimate from block 512 may be generated using the tracking tools described above or, in some examples, a cardiac rate estimate may be generated directly from a peak selector that assesses a self-correlation function.

20 The therapy decision 506 may use each of these different calculations in various approaches to identifying whether therapy is needed. For example, one of the rates may be used to double check the other, or the rates may be compared to identify a match. If the rates do not match, additional analysis may be performed using, for example, additional sensing inputs, such as a motion sensor or blood pressure or oxygenation sensor. If the rates both suggest therapy is needed (whether matching or
25 not), therapy functions may then be called. Other approaches are noted above.

In one example, if the dominant peak test is applied and met by a dominant peak, then therapy decision 506 may be configured to treat the estimated cardiac rate associated with the dominant peak as more reliable than a rate generated using an R-wave detection from block 500. In another example, a peak which passes the picket
30 test may be treated in the therapy decision 506 as more reliable than a rate generated using an R-wave detection from block 500. In yet another example, the outputs of the

peak selection may be treated as less reliable than the R-wave detection outputs until a track is declared via the methods of Figure 8A-8B, and then only if the peak selection output falls within a defined track.

5 Still other examples may have multiple analytical courses depending on the status of the R-wave detection rate, tracking and peak selection outputs. For example, the following rules may apply in various examples:

- If both R-wave detection rate and Self-Correlation Rate match and are high rates, the high rate is confirmed, suggesting tachyarrhythmia
- If R-wave detection suggests high rate but Self-Correlation Rate is lower, 10 additional analysis is required (waiting time, detected event width or morphology analysis) before the high rate is treated as valid if either:
 - o the Self-Correlation Rate is based on a rate estimate falling within a valid track (the rate estimate being either a candidate or selected peak from peak analysis); or
 - o the Self-Correlation Rate is based on a selected peak that passes 15 one of the picket test or the dominant peak test
- If R-wave detection rate is low, but Self-Correlation Rate is high, additional analysis (waiting time, detected event width or morphology analysis) is required before the high rate is treated as valid unless the Self- 20 Correlation Rate is within a declared track and is based on a peak that passes the picket test (whether directly or via the large tachy peak test)

In another example, tracking is omitted and the following rules may apply:

- The rate calculated using R-wave detection is treated as valid if it is high and the Self-Correlation rate exceeds a tachy threshold (whether the rates 25 match or not);
- The rate calculated using R-wave detection is treated as valid if it is high and the Self-Correlation test fails to meet either the picket test or dominant peak test;
- The rate calculated using the Self-Correlation test is treated as valid if it is 30 lower than the R-wave detection rate and below the tachy threshold and either passes the picket test or passes the dominant peak test

Other combinations are also possible within the scope of the present invention.

In one example, if the Self-Correlation analysis is called periodically, and if the Self-Correlation rate is calculated with high confidence, then the Self-Correlation rate takes the place of the rate calculated using R-wave detection until the next
5 iteration of the Self-Correlation analysis. In a system using an NID or X-out-of-Y filter, then the Self-Correlation analysis rate can be treated as occurring repeatedly during the time period where the R-wave detection is replaced. For example, if Self-Correlation determines a rate of 180 beats-per-minute, and the Self-Correlation function is called at one second intervals, the NID or X-out-of-Y filter analysis would
10 add three events at 180 beats-per-minute during the one second interval between iterations of the Self-Correlation analysis.

The therapy decision 506 may determine whether the cardiac rate as estimated by one or both of blocks 502/512 exceeds a therapy threshold using, for example, a direct calculation of one rate, or a calculation across several iterations using one or
15 more of an NID or X-out-of-Y filter as discussed above. The therapy decision may combine rate with morphology (shape) information gathered from the cardiac signal. In some examples, the therapy decision 506 can set two or more rate boundaries, including one or more of a shock-only boundary, in which rates above a threshold are deemed necessitating high energy cardioversion or defibrillation shock, a VT zone in
20 which a lower energy therapy such as anti-tachycardia pacing is applied, and a conditional zone in which additional analysis of a combination of shape elements (template matching, width, interval stability, amplitude, etc.) as well as rate is performed. The therapy decision 506 may integrate additional sensor inputs or inputs from separate devices, such as blood oxygenation, pressure, color, etc. measurements,
25 measurements from a separate device such as a pressure monitor, leadless pacer, etc., or measurements from a position or movement sensor which can be separately provided in the patient's or integrated in a single device with the rest of the system that performs the self-correlation and other functions described above.

30

Various Notes & Examples

A first non-limiting example takes the form of an implantable medical device system (12, 14, 32, 34) configured for iterative analysis of cardiac signals comprising: a plurality of electrodes (16, 18, 20, 36, 38, 40, 42) for sensing cardiac signals; self-correlation means for generating a self-correlation function from the sensed cardiac signals, the self-correlation function having amplitudes as a function of lag depth; and analysis means for determining one or more estimates of cardiac rate using outputs of the self-correlation means; wherein the self-correlation means includes: sample selection means to select a first data set of the cardiac signal having a first length, N, and signal selection means to select a second data set of the cardiac signal having a second length, in which the second length longer than the first length, and the second data set includes the first data set; comparison means to perform repeated subtraction of the first data set from the second data set at a series of lag depths from approximately zero to approximately N, to generate the self-correlation function. A detailed example of the first non-limiting example is illustrated in the combination of Figures 1, 2 and 14, with electrodes shown in Figures and 2 in various locations and positions, and self-correlation means indicated in block 322, having selection means 330 for selecting the first and second data sets and comparison means 332 for comparing the data sets to one another, and analysis means illustrated at 324 generating a rate output 326. Certain variants on the first example may include having the second length be approximately twice the first length, and using an absolute area of difference calculation as the subtraction.

A second non-limiting example takes the form of a system (12, 14, 32, 34) as in the first non-limiting example, wherein the analysis means comprises peak selector means for identifying amplitude peaks in the self-correlation function and finding a first estimate of cardiac rate. Figure 14 is illustrative, with peak selector means 340 as part of the analysis means 324.

A third non-limiting example takes the form of a system as in the second non-limiting example, further comprising normalizing means for scaling an output from the comparison means. Figure 14 is illustrative, with normalizing means 334 as part of the self-correlation means 322.

A fourth non-limiting example takes the form of a system as in the third non-limiting example wherein the normalizing means is configured to scale the output of the comparison means to a scale between 0 and N; and the peak selector means is configured to ignore any peak less than 0.3 times N.

5 A fifth non-limiting example takes the form of a system as in any of the second to fourth non-limiting examples wherein the analysis means comprises tracking means for tracking outputs of the peak selector means to generate cardiac rate estimates using several iterations of the peak selector means outputs. Figure 14 is illustrative, with tracking means 342 as part of the analysis means 324.

10 A sixth non-limiting example takes the form of a system as in any of the second to fifth non-limiting examples, wherein the peak selector means is operable to find the first estimate of cardiac rate by identifying the lag depth associated with an identified amplitude peak, converting the lag depth into a time interval, and calculating rate from the time interval. A seventh non-limiting example takes the form of a system as in any of the first to sixth non-limiting examples, wherein the first data set comprises data from the sensed cardiac signals covering approximately two seconds of data, and the second data set comprises data from the sensed cardiac signals covering approximately four seconds of data. An eighth non-limiting example takes the form of a system as in any of the first to sixth non-limiting examples, wherein the first data set comprises data from the sensed cardiac signals covering approximately one second of data, and the second data set comprises data from the sensed cardiac signals covering approximately two seconds of data. A ninth non-limiting example takes the form of a system as in any of the first to eighth non-limiting examples, wherein the self-correlation means is configured to first down-sample the sensed cardiac signals prior to the subtraction to reduce computational burden.

20 A tenth non-limiting example takes the form of a system as in any of the first to ninth non-limiting examples, further comprising decision means for determining whether cardiac therapy is needed. Figure 16 is illustrative as including a therapy decision means 506.

An eleventh non-limiting example takes the form of a system as in any of the first to tenth non-limiting example, further comprising R-wave detection means for detecting R-waves in order to identify a cardiac rate therefrom, wherein the decision means is configured to select from a cardiac rate estimated using the R-wave
5 detection means, and a cardiac rate estimated using the self-correlation function. Figure 16 is illustrative as including R-wave detection means 500, 502, 504 for detecting R-waves and identifying a cardiac rate therefrom, with therapy decision means 506 taking rate information from both the R-wave detection 500, 502, 504 and self-correlation 510, 512, 514 and making a therapy decision.

10 A twelfth non-limiting example takes the form of a system as in the eleventh non-limiting example, wherein the R-wave detection means is operable to compare sensed cardiac signals to a time-varying threshold in order to generate detections of heart beats, such that cardiac rate can be calculated by identifying intervals between detected heart beats.

15 A thirteenth non-limiting example takes the form of a system as in any of the first to twelfth non-limiting examples, wherein the implantable medical device system comprises a canister housing operational circuitry including at least the self-correlation means and analysis means, and a lead system including at least some of the plurality of electrodes. Figures 1-2 illustrate canisters and lead systems.

20 A fourteenth non-limiting example takes the form of a system as in the thirteenth non-limiting example, wherein the canister and lead system are configured for implantation as a subcutaneous-only system. A subcutaneous-only system is shown in Figure 1.

25 A fifteenth non-limiting example takes the form of a system as in the thirteenth non-limiting example, wherein the canister and lead system are configured for implantation as a transvenous system. A transvenous system is shown in Figure 2.

A sixteenth non-limiting example takes the form of a method of iterative analysis of cardiac signals comprising: sensing cardiac signals from a plurality of electrodes; generating a self-correlation function from the sensed cardiac signals, the self-correlation function having amplitudes as a function of lag depth; and
30 determining a first estimate of cardiac rate using the self-correlation function; wherein

the step of generating the self-correlation function includes: selecting a first data set from the cardiac signal having a first length, N , and a second data set from the cardiac signal having a second length approximately twice the length of the first length, wherein the second data set includes the first data set; repeatedly subtracting the first
5 data set from the second data set at a series of lag depths from approximately zero to approximately N , to generate the self-correlation function.

A seventeenth non-limiting example takes the form of a method as in the sixteenth non-limiting example further comprising identifying amplitude peaks in the self-correlation function and finding a first estimate of cardiac rate. A eighteenth non-
10 limiting example takes the form of a method as in the sixteenth or seventeenth non-limiting examples wherein the step of generating the self-correlation function includes normalizing results of the repeated subtracting step.

A nineteenth non-limiting example takes the form of a method as in any of the sixteenth to eighteenth non-limiting examples wherein the step of determining a first
15 estimate of cardiac rate includes identifying a peak in the self-correlation having a first lag depth, wherein the peak is analytically determined to be likely to indicate reliably high correlation of the first data set to the second data set at the first lag depth, and calculating the cardiac rate using the first lag depth.

A twentieth non-limiting example takes the form of a method comprising
20 repeatedly performing a method as in any one of the sixteenth to nineteenth non-limiting examples, comparing the first lag depth as identified at the first time to the first lag depth as identified at the second time; and if the comparing step finds similarity of the first lag depths, determining that a reliable rate is likely.

A twenty-first non-limiting example takes the form of a method as in any of
25 the sixteenth to twentieth non-limiting examples, wherein the first data set comprises data from the sensed cardiac signals covering approximately two seconds of data, and the second data set comprises data from the sensed cardiac signals covering approximately four seconds of data.

A twenty-second non-limiting example takes the form of a method as in any of
30 the sixteenth to twentieth non-limiting examples, wherein the first data set comprises data from the sensed cardiac signals covering approximately one second of data, and

the second data set comprises data from the sensed cardiac signals covering approximately two seconds of data.

A twenty-third non-limiting example takes the form of a method as in any of the sixteenth to twenty-second non-limiting examples, further comprising determining
5 whether cardiac therapy is needed using at least the first estimate of cardiac rate.

A twenty-fourth non-limiting example takes the form of a method as in any of the sixteenth to twenty-third non-limiting examples, further comprising: detecting R-waves in order to identify a second estimate of cardiac rate therefrom; and selecting
10 from between the first estimate of cardiac rate and the second estimate of cardiac rate to yield a final estimate of cardiac rate.

A twenty-fifth non-limiting example takes the form of an implantable medical device comprising sensing circuitry and a processor and a non-transitory medium with instructions contained therein for implementation by the processor, the processor configured to operate on the instructions to use the sensing circuitry and therapy output circuitry as follows: sensing cardiac signals with the sensing circuitry; generating a self-correlation function from the sensed cardiac signals, the self-correlation function having amplitudes as a function of lag depth, by: selecting a first data set from the cardiac signal having a first length, N , and a second data set from the cardiac signal having a second length approximately twice the length of the first length, wherein the second data set includes the first data set; repeatedly subtracting the first data set from the second data set at a series of lag depths from approximately zero to approximately N , to generate the self-correlation function; and determining a first estimate of cardiac rate using the self-correlation function.

Numerous additional examples take the form of implantable cardiac systems comprising a canister housing operational circuitry, the operational circuitry being configured for use with a plurality of electrodes, wherein operational circuitry is configured to perform the methods of any of the sixteenth to twenty-fourth non-
15 limiting examples.

Each of these non-limiting examples can stand on its own, or can be combined in various permutations or combinations with one or more of the other examples.

The above detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention can be practiced. These embodiments are also referred to herein as “examples.” Such examples can include
5 elements in addition to those shown or described. However, the present inventors also contemplate examples in which only those elements shown or described are provided. Moreover, the present inventors also contemplate examples using any combination or permutation of those elements shown or described (or one or more aspects thereof), either with respect to a particular example (or one or more aspects thereof), or with respect to other examples (or one or more aspects thereof) shown or
10 described herein.

In the event of inconsistent usages between this document and any documents so incorporated by reference, the usage in this document controls.

In this document, the terms “a” or “an” are used, as is common in patent
15 documents, to include one or more than one, independent of any other instances or usages of “at least one” or “one or more.” In this document, the term “or” is used to refer to a nonexclusive or, such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated. In this document, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms
20 “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, composition, formulation, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as
25 labels, and are not intended to impose numerical requirements on their objects.

Method examples described herein can be machine or computer-implemented at least in part. Some examples can include a computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples. An implementation of such
30 methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for

performing various methods. The code may form portions of computer program products. Further, in an example, the code can be tangibly stored on one or more volatile, non-transitory, or non-volatile tangible computer-readable media, such as during execution or at other times. Examples of these tangible computer-readable
5 media can include, but are not limited to, hard disks, removable magnetic disks, removable optical disks (e.g., compact disks and digital video disks), magnetic cassettes, memory cards or sticks, random access memories (RAMs), read only memories (ROMs), and the like.

The above description is intended to be illustrative, and not restrictive. For
10 example, the above-described examples (or one or more aspects thereof) may be used in combination with each other. Other embodiments can be used, such as by one of ordinary skill in the art upon reviewing the above description. The Abstract is provided to comply with 37 C.F.R. §1.72(b), to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it
15 will not be used to interpret or limit the scope or meaning of the claims. Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following
20 claims are hereby incorporated into the Detailed Description as examples or embodiments, with each claim standing on its own as a separate embodiment, and it is contemplated that such embodiments can be combined with each other in various combinations or permutations. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which
25 such claims are entitled.

THE CLAIMED INVENTION IS:

1. An implantable medical device system (12, 14, 32, 34) configured for iterative analysis of cardiac signals comprising:
 - a plurality of electrodes (16, 18, 20, 36, 38, 40, 42) for sensing cardiac signals;
 - self-correlation means for generating a self-correlation function from the sensed cardiac signals, the self-correlation function having amplitudes as a function of lag depth; and
 - analysis means for determining one or more estimates of cardiac rate using outputs of the self-correlation means;
 - wherein the self-correlation means includes:
 - sample selection means to select a first data set of the cardiac signal having a first length, N, and signal selection means to select a second data set of the cardiac signal having a second length, in which the second length is longer than the first length, and the second data set includes the first data set;
 - comparison means to perform repeated subtraction of the first data set from the second data set at a series of lag depths from approximately zero to approximately N, to generate the self-correlation function.
2. An implantable medical device system (12, 14, 32, 34) as in claim 1 wherein the analysis means comprises peak selector means for identifying amplitude peaks in the self-correlation function and finding a first estimate of cardiac rate.
3. An implantable medical device system as in claim 2 further comprising normalizing means for scaling an output from the comparison means.
4. An implantable medical device system as in any of claims 1-3 wherein the second length is approximately twice the first length.
5. An implantable medical device system (12, 14, 32, 34) as in any of claims 2-4 wherein the analysis means comprises tracking means for tracking outputs of the peak

selector means to generate cardiac rate estimates using several iterations of the peak selector means outputs.

6. An implantable medical device system (12, 14, 32, 34) as in any of claims 2-5 wherein the peak selector means is operable to find the first estimate of cardiac rate by identifying the lag depth associated with an identified amplitude peak, converting the lag depth into a time interval, and calculating rate from the time interval.

7. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-6 wherein the first data set comprises data from the sensed cardiac signals covering approximately two seconds of data, and the second data set comprises data from the sensed cardiac signals covering approximately four seconds of data.

8. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-6 wherein the first data set comprises data from the sensed cardiac signals covering approximately one second of data, and the second data set comprises data from the sensed cardiac signals covering approximately two seconds of data.

9. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-8 wherein the self-correlation means is configured to first down-sample the sensed cardiac signals prior to the subtraction to reduce computational burden.

10. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-9 further comprising decision means for determining whether cardiac therapy is needed.

11. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-10 further comprising R-wave detection means for detecting R-waves in order to identify a cardiac rate therefrom, wherein the decision means is configured to select from a cardiac rate estimated using the R-wave detection means, and a cardiac rate estimated using the self-correlation function.

12. An implantable medical device system (12, 14, 32, 34) as in claim 11 wherein the R-wave detection means is operable to compare sensed cardiac signals to a time-varying threshold in order to generate detections of heart beats, such that cardiac rate can be calculated by identifying intervals between detected heart beats.

13. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-12 wherein the step of repeated subtraction is performed as an absolute value of the difference of the first data set and second data set.

14. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-13, wherein:

the implantable medical device system comprises a canister housing operational circuitry including at least the self-correlation means and analysis means, and a lead system including at least some of the plurality of electrodes; and

the canister and lead system are configured for implantation as a subcutaneous-only system.

15. An implantable medical device system (12, 14, 32, 34) as in any of claims 1-13, wherein:

the implantable medical device system comprises a canister housing operational circuitry including at least the self-correlation means and analysis means, and a lead system including at least some of the plurality of electrodes; and

the canister and lead system are configured for implantation as a transvenous system.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/045159

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61B5/00 A61B5/0245 A61B5/04 A61N1/37
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 A61B A61N G06K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2012/197151 A1 (SCHATZ KELLY [US] ET AL) 2 August 2012 (2012-08-02) paragraph [0010] paragraph [0015] - paragraph [0023]; figures 2, 3 -----	1-15
Y	US 2006/004547 A1 (MOSTAFAVI HASSAN [US]) 5 January 2006 (2006-01-05) paragraph [0026] - paragraph [0027] paragraph [0045] - paragraph [0049] paragraph [0060] - paragraph [0068]; figure 5 -----	1,2,4-8, 10,13-15
Y	US 2009/315889 A1 (TOGNOLA DIEGO GIUSEPPE [AU]) 24 December 2009 (2009-12-24) paragraph [0070] - paragraph [0080] paragraph [0131]; figures 10, 17, 20 ----- -/--	1-3,5,6, 9-15

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 26 November 2015	Date of mailing of the international search report 08/12/2015
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Sigurd, Karin

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/045159

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2012/271367 A1 (QU FUJIAN [US] ET AL) 25 October 2012 (2012-10-25) paragraph [0031] - paragraph [0038] paragraph [0060] - paragraph [0064]; figure 2B -----	1-15
A	US 5 857 977 A (CASWELL STEPHANIE A [US] ET AL) 12 January 1999 (1999-01-12) column 3, line 61 - column 4, line 16 column 9, line 14 - line 40 column 10, line 50 - line 64; figure 2 -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2015/045159

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2012197151 A1	02-08-2012	US 2007067005 A1 US 2009275811 A1 US 2012197151 A1	22-03-2007 05-11-2009 02-08-2012

US 2006004547 A1	05-01-2006	AT 316403 T AU 771038 B2 AU 1228600 A CA 2348091 A1 DE 69929628 T2 EP 1123137 A1 JP 4391023 B2 JP 2002528193 A US 6621889 B1 US 6959266 B1 US 2006004547 A1 WO 0024466 A1	15-02-2006 11-03-2004 15-05-2000 04-05-2000 21-09-2006 16-08-2001 24-12-2009 03-09-2002 16-09-2003 25-10-2005 05-01-2006 04-05-2000

US 2009315889 A1	24-12-2009	EP 1904816 A1 JP 2009501909 A US 2009315889 A1 WO 2007009177 A1	02-04-2008 22-01-2009 24-12-2009 25-01-2007

US 2012271367 A1	25-10-2012	NONE	

US 5857977 A	12-01-1999	AU 4147497 A US 5857977 A WO 9805254 A1	25-02-1998 12-01-1999 12-02-1998

专利名称(译)	具有自相关装置和用于估计心率的分析装置的可植入医疗装置		
公开(公告)号	EP3182883A1	公开(公告)日	2017-06-28
申请号	EP2015756284	申请日	2015-08-13
[标]申请(专利权)人(译)	卡梅伦保健公司		
申请(专利权)人(译)	CAMERON HEALTH , INC.		
当前申请(专利权)人(译)	CAMERON HEALTH , INC.		
[标]发明人	KRZYSZTOF SIEJKO Z HUELSKAMP PAUL		
发明人	KRZYSZTOF, SIEJKO Z. HUELSKAMP, PAUL		
IPC分类号	A61B5/00 A61B5/0245 A61B5/04 A61N1/37		
CPC分类号	A61B5/0245 A61B5/04011 A61B5/04012 A61B5/04014 A61B5/0422 A61B5/04525 A61B5/0456 A61B5/046 A61B5/0464 A61B5/4836 A61B5/686 A61B5/7246 A61N1/3704 A61N1/3925 A61N1/3956 A61N1/3987 G06F17/16 G06F19/3418 G16H10/60 G16H20/30 G16H40/67 G06F17/11		
优先权	62/038440 2014-08-18 US 62/038437 2014-08-18 US 62/038438 2014-08-18 US 14/819889 2015-08-06 US		
外部链接	Espacenet		

摘要(译)

公开了一种可植入医疗设备，该设备包括用于感测心脏信号的电极（320），用于从感测的心脏信号生成自相关函数的自相关装置（322）和用于确定一个或多个估计的分析装置（324）心率（326）使用自相关装置的输出。峰值选择器装置（340）和跟踪装置（342）也可以作为次要元件包括在内。该装置可以提供心率的替代计算作为独立的速率检测器或用于双重检查其他速率计算的装置。